West Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results, Misses Estimates By $0.25 EPS

West Pharmaceutical Services (NYSE:WST) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.77 by ($0.25), Briefing.com reports. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The company had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. During the same quarter in the prior year, the firm earned $2.11 earnings per share. The company’s revenue for the quarter was down 6.9% on a year-over-year basis. West Pharmaceutical Services updated its FY 2024 guidance to 6.350-6.650 EPS.

West Pharmaceutical Services Price Performance

Shares of West Pharmaceutical Services stock traded up $7.63 during trading on Friday, hitting $284.79. 1,190,411 shares of the company were exchanged, compared to its average volume of 563,505. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services has a fifty-two week low of $265.00 and a fifty-two week high of $415.73. The stock has a market capitalization of $20.74 billion, a price-to-earnings ratio of 37.57, a P/E/G ratio of 5.75 and a beta of 1.00. The firm has a 50 day moving average price of $324.09 and a 200 day moving average price of $355.75.

Insider Buying and Selling

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares in the company, valued at approximately $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.